Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model

Vaccine

Volumn 28, Issue 3, 2010, Pages 650-656

  Sabarth, Nicolas ^a   Howard, M Keith ^a   Savidis Dacho, Helga ^a   van Maurik, André ^a   Barrett, P Noel ^a   Kistner, Otfried ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

H5N1 avian influenza; Heterologous prime boost immunization; Single immunization

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; VERO CELL;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINATION;

EID: 71149099301     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.105     Document Type: Article

References (32)

1. World Health Organization. WHO global preparedness plan. The role of WHO and recommendations for national measures before and during pandemics. http://www who int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5 pdf; 2005. p. 1-50.
2. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358 (2008) 261-273
3. World Health Organization. WHO. Antigenic and genetic characterization of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines. http://www.who.int/entity/csr/disease/avianinfluenza/guidelines/H5Vaccine VirusUpdate20080214.pdf; 2008.
4. Meiklejohn G., Eickhoff T.C., and Graves P. Antigenic drift and efficacy of influenza virus vaccines. J Infect Dis 138 (1978) 618-624
5. Howard M.K., Kistner O., and Barrett P.N. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 389 5 (2008) 569-577
6. Kistner O., Howard M.K., Spruth M., Wodal W., Brühl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25 (2007) 6028-6036
7. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 24 (2008) 2573-2584
8. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., and Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8 10 (2008) 650-658
9. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 9-10 (1998) 960-968
10. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493-497
11. Ting N. Dose finding in drug development (2006), Springer, New York
12. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
13. Droebner K., Haasbach E., Fuchs C., Weinzierl A.O., Stevanovic S., Büttner M., et al. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 26 52 (2008) 6965-6974
14. Desheva J.A., Lu X.H., Rekstin A.R., Rudenko L.G., Swayne D.E., Cox N.J., et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24 47-48 (2006) 6859-6866
15. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., and Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194 2 (2006) 159-167
16. Suguitan Jr. A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 9 (2006) e360
17. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195 11 (2007) 1598-1606
18. Schwartz J.A., Buonocore L., Roberts A., Suguitan Jr. A., Kobasa D., Kobinger G., et al. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366 1 (2007) 166-173
19. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3 1 (2008) e1501
20. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
21. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198 5 (2008) 642-649
22. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., and Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3 2 (2008) e1665
23. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
24. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 9540 (2006) 991-997
25. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
26. Rao S., Kong W.P., Wei C.J., Yang Z.Y., Nason M., Styles D., et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 Avian influenza infection in chickens and mice. PLoS Med 3 9 (2008) e2432
27. Crevar C.J., and Ross T.M. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 5 1 (2008) 131
28. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26 42 (2008) 5393-5399
29. Hoelscher M.A., Singh N., Garg S., Jayashankar L., Veguilla V., Pandey A., et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 197 8 (2008) 1185-1188
30. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 359 15 (2008) 1631-1633
31. Murakami S., Iwasa A., Iwatsuki-Horimoto K., Ito M., Kiso M., Kida H., et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26 50 (2008) 6398-6404
32. Taubenberger J.K., and Morens D.M. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 12 1 (2006) 15-22